Results: Our study revealed a significant upregulation of RNASEK (P < 0.05) in six cancers: bladder (BLCA), cholangiocarcinoma (CHOL), esophageal (ESCA), head/neck squamous cell (HNSC), liver (LIHC), and thyroid (THCA). Here, RNASEK is linked to bladder transitional cell carcinoma.